Infection and Immunity, April 2000, p. 1753-1759, Vol. 68, No. 4
Department of Inflammation, Eijkman Winkler
Institute, University Medical Center, 3584 CX Utrecht, The Netherlands
Received 3 May 1999/Returned for modification 1 September
1999/Accepted 12 January 2000
Although serum amyloid P component (SAP) is known to bind many
ligands, its biological function is not yet clear. Recently, it was
demonstrated that SAP binds to lipopolysaccharide (LPS). In the present
study, SAP was shown to bind to gram-negative bacteria expressing short
types of LPS or lipo-oligosaccharide (LOS), such as Salmonella
enterica serovar Copenhagen Re and Escherichia coli J5, and also to clinical isolates of Haemophilus
influenzae. It was hypothesized that SAP binds to the bacteria
via the lipid A part of LPS or LOS, since the htrB mutant
of the nontypeable H. influenzae strain NTHi 2019-B29-3,
which expresses a nonacetylated lipid A, did not bind SAP. This was in
contrast to the parental strain NTHi 2019. The binding of SAP resulted
in a clear inhibition of the deposition of complement component C3 on
the bacteria. SAP inhibited only the activation of the classical
complement pathway; the alternative route remained unaffected. In the
classical route, SAP prevented the deposition of the first complement
component, Clq, probably by interfering with the binding of Clq to LPS.
Since antibody-mediated Clq activation was not inhibited by SAP, SAP seems to inhibit only the LPS-induced classical complement pathway activation. The SAP-induced inhibition of C3 deposition strongly diminished the complement-mediated lysis as well as the phagocytosis of
the bacteria. The binding of SAP to gram-negative bacteria, therefore,
might influence the pathophysiology of an infection with such bacteria.
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Serum Amyloid P Component Bound to Gram-Negative
Bacteria Prevents Lipopolysaccharide-Mediated Classical Pathway
Complement Activation
*
Corresponding author. Mailing address: Eijkman Winkler
Institute, Dept. of Inflammation, G04.614, University Medical Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Phone: (31) 30-2507627. Fax: (31) 30-2541770. E-mail:
c.j.c.dehaas{at}lab.azu.nl.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»